Literature DB >> 21546046

[Management of brain metastases from non-small cell lung carcinoma].

O Bailon1, A Kallel, K Chouahnia, S Billot, D Ferrari, A-F Carpentier.   

Abstract

INTRODUCTION: In France, approximately 30,000 new patients per year develop brain metastases (BM), most of them resulting from a lung cancer. STATE OF THE ART: Surgery and radiosurgery of all the BM must be considered when possible. In other cases, whole brain radiotherapy remains the standard of care. PERSPECTIVES: The role of chemotherapy, poorly investigated so far, should be revisited.
CONCLUSION: This review focused on BM secondary to a non-small cell lung carcinoma.
Copyright © 2011 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21546046     DOI: 10.1016/j.neurol.2011.01.017

Source DB:  PubMed          Journal:  Rev Neurol (Paris)        ISSN: 0035-3787            Impact factor:   2.607


  5 in total

1.  Targeted sequencing reveals distinct pathogenic variants in Chinese patients with lung adenocarcinoma brain metastases.

Authors:  Yanchun Ma; Kun Chen; Zhenhua Yang; Ming Guan
Journal:  Oncol Lett       Date:  2018-01-25       Impact factor: 2.967

2.  Cerebral staging of lung cancer: is one single contrast-enhanced T1-weighted three-dimensional gradient-echo sequence sufficient?

Authors:  Mickaël Ohana; Mi-Young Jeung; Gauthier Bazille; Catherine Roy
Journal:  Neuroradiology       Date:  2014-05-15       Impact factor: 2.804

Review 3.  Methods and results of locoregional treatment of brain metastases in patients with non-small cell lung cancer.

Authors:  Anna Patla; Tomasz Walasek; Jerzy Jakubowicz; Paweł Blecharz; Jerzy Władysław Mituś; Anna Mucha-Małecka; Marian Reinfuss
Journal:  Contemp Oncol (Pozn)       Date:  2016-12-20

Review 4.  Systemic treatment of non-small cell lung cancer brain metastases.

Authors:  Ida Cedrych; Maksymilian A Kruczała; Tomasz Walasek; Jerzy Jakubowicz; Paweł Blecharz; Marian Reinfuss
Journal:  Contemp Oncol (Pozn)       Date:  2016-12-20

5.  EGFR, KRAS, BRAF, and HER-2 molecular status in brain metastases from 77 NSCLC patients.

Authors:  Claire Villalva; Valérie Duranton-Tanneur; Karline Guilloteau; Fanny Burel-Vandenbos; Michel Wager; Jérôme Doyen; Pierre Marie Levillain; Denys Fontaine; Hélène Blons; Florence Pedeutour; Lucie Karayan-Tapon
Journal:  Cancer Med       Date:  2013-04-23       Impact factor: 4.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.